China’s Maternity and Baby Market (Part II): Key Segments and Opportunities for Foreign Brands

June 30, 2026 Posted by China Briefing Written by Giulia Interesse Reading Time: 4 minutes

China’s baby market opportunities for foreign brands are concentrated in five segments — infant formula, maternal nutrition, baby care, postpartum services, and assisted reproduction — each with its own regulatory profile, competitive dynamics, and entry logic. Part II of this two-part guide examines each key segment in detail, maps the real challenges foreign entrants face, and identifies where the strongest opportunities lie.

Plan to establish a business in China? Explore how we can support →

China’s maternity and baby market is shifting from a volume story to a value story. That transition plays to the strengths of foreign brands with premium positioning, clinical credibility, and category expertise. Part I of this series set out the structural context: the demographic trajectory, the policy environment, the consumer profile, and the market’s overall size and channel dynamics. This article moves from context to action.

The sections below examine the five key product and service segments in turn — infant formula, diapers and baby care, maternal and infant nutrition, postpartum and childcare services, and assisted reproduction — before addressing the challenges that apply across the market and the entry approaches most relevant to foreign brands and investors.

DOING BUSINESS IN CHINA EXPLORE IN-DEPTH INVESTMENT AND BUSINESS GUIDES.

Explore vital economic, geographic, and regulatory insights for business investors, managers, or expats to navigate China’s business landscape. Our Online Business Guides offer explainer articles, news, useful tools, and videos from on-the-ground advisors who contribute to the Doing Business in China knowledge. Start exploring

Key product and service segments

Infant formula

Infant formula remains the anchor of the market. China’s infant milk formula market was valued at roughly RMB 129 billion (around US$18 billion) in 2025—the single largest such market in the world by revenue—and is projected to grow at close to 8 percent annually through 2030 as premiumization (HMOs, MFGM, and probiotics) lifts average selling prices. Best fit for foreign entrants: premium and imported positioning, clinical differentiation, cross-border e-commerce to test demand, and licensing or joint-venture models with established domestic players.

Diapers and baby personal care

Have Any Questions? Reach out to our local experts→

Diapers and wipes represent classic inelastic, high-frequency demand. China’s baby diaper market was estimated at around US$8.9 billion in 2024 and is forecast to approach US$13.6 billion by the early 2030s. International incumbents such as Procter & Gamble (Pampers) and Kimberly-Clark (Huggies) compete with domestic challengers, while adjacent baby skincare and toiletries are growing as parents extend clean-label expectations to their children. Best fit for foreign entrants: premium and specialty niches (sensitive-skin, eco-friendly, clean-label) where trust and quality outweigh domestic price advantages.

Maternal and infant nutrition

The nutrition segments, which include prenatal and postnatal maternal supplements and infant nutrition, are the fastest-growing parts of the market, supported by rising demand for health supplements and the broader “mother and baby” shift.

Best fit for foreign entrants: differentiated, clinically framed products launched through content commerce and mother-and-baby specialty chains, where physician endorsements and mom-community advocacy are the most effective trust mechanisms.

Maternity, postpartum, and childcare services

Spending begins before birth and extends well past it. Maternal nutrition, maternity apparel, and—distinctively in China—premium postpartum confinement services (“yuesao” caregivers and dedicated “yuezi” confinement centers) represent a premiumizing, low-penetration services market. Formal childcare and daycare (“tuoyu”) for the under-threes is a stated government priority, expanding alongside early-childhood education and children’s insurance.

Best fit for foreign entrants: premium service know-how delivered via management partnerships, training, and brand-licensing or JV models rather than standalone direct entry.

Assisted reproduction (ART)

Assisted reproduction is a fast-growing frontier driven by rising infertility (now affecting nearly one in six couples), delayed parenthood, and expanding insurance coverage. China’s ART services market exceeded RMB 34.9 billion (US$4.79 billion) in 2024 and is projected to grow at around 7.8 percent annually to 2030, while the IVF segment alone is forecast to roughly double by the early 2030s.

With over half of ART materials and equipment currently imported, the segment offers exposure to the maternity theme that is largely decoupled from birth volumes.

Best fit for foreign entrants: medical devices and equipment, specialized fertility pharmaceuticals, clinical services and partnerships, and R&D collaboration in genetics and reproductive science.

Key challenges when entering China’s maternity and baby market

Despite its momentum, the market presents real challenges that foreign entrants should weigh carefully:

Demographic shifts: The most fundamental is the structural demographic constraint. With the number of women of childbearing age falling, marriage rates near record lows, and the brief 2024 rebound already reversed in 2025, brands counting on a recovery in birth volumes are likely to be disappointed; growth must come from share-of-wallet, not headcount.
Competitive landscape: Competition is intense and increasingly price-stratified. Resurgent domestic brands often undercut imports, and the rapid online shift (together with platform-driven price parity) compresses margins for those without clear differentiation.
Regulatory complexity: The regulatory burden is also rising: formula registration, the 2023 standards transition, and the 2027 labeling overhaul demand continuous compliance investment. Trust remains fragile, as periodic product-safety incidents can quickly reshape demand.
Uneven access: Premium demand and ART clinics concentrate in tier-1 and tier-2 cities, while lower-tier and rural markets remain comparatively underserved, requiring tailored distribution and pricing.

Opportunities for foreign businesses and investors

Premium and imported infant formula, differentiated on clinically validated ingredients (HMOs, MFGM) and tested through cross-border e-commerce before onshore registration.
Maternal and infant nutrition, the fastest-growing segment, where prenatal and postnatal supplements reward precise, stage-specific positioning.
Baby personal care, especially sensitive-skin, eco-friendly, and clean-label products, where trust outweighs price.
Postpartum and childcare services, including confinement care, daycare, and early education, via management partnerships and JV or licensing models.
Assisted reproduction, spanning medical devices, fertility pharmaceuticals, clinical services, and R&D, where reliance on imports creates room for foreign suppliers.
Cross-border and content commerce enablement, helping brands reach digital-native parents through Xiaohongshu, Douyin, and subscription replenishment models.

Above all, success depends on not treating China as a single national market: winners segment by city tier, channel, product category, and trust proposition. The market will reward those who sell not just to babies, but to a generation of demanding, well-informed parents.

For the structural context behind these opportunities — including the demographic forces, policy landscape, and market-level data that shape the sector — see Part I of this series.